Related Experiment Video
Updated: May 9, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
Rationale and early clinical data on IL-17 blockade in psoriasis
Steven M Nwe1, Amanda H Champlain, Kenneth B Gordon
1Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N. St. Clair St., Suite 1600, Chicago, IL 60611, USA.
Abstract:
Psoriasis vulgaris is a chronic, immune-mediated, inflammatory disease that affects between 2 and 3% of the US population. Often severely physically and emotionally debilitating, psoriasis has driven investigators to strive to better characterize its complex immune pathogenesis. Some of the most promising and exciting advances have occurred in the last decade with recognition of the IL-23/Th17 pathway in disease initiation, progression and maintenance. Biologic therapies targeting various points in the pathway have met with success, prompting the study of the safety and efficacy of IL-17 blockade for moderate-to-severe plaque psoriasis. This article will review the rationale and early clinical data on IL-17 blockade in psoriasis.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF